Skip to main content
Erschienen in: Current Psychiatry Reports 5/2011

01.10.2011

Dietary and Nutritional Treatments for Attention-Deficit/Hyperactivity Disorder: Current Research Support and Recommendations for Practitioners

verfasst von: Elizabeth A. Hurt, L. Eugene Arnold, Nicholas Lofthouse

Erschienen in: Current Psychiatry Reports | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Evidence for dietary/nutritional treatments of attention-deficit/hyperactivity disorder (ADHD) varies widely, from double-blind, placebo-controlled trials to anecdotal. In guiding patients, clinicians can apply the SECS versus RUDE rule: treatments that are Safe, Easy, Cheap, and Sensible (SECS) require less evidence than those that are Risky, Unrealistic, Difficult, or Expensive (RUDE). Two nutritional treatments appear worth general consideration: Recommended Daily Allowance/Reference Daily Intake multivitamin/mineral supplements as a pediatric health intervention not specific to ADHD and essential fatty acids, especially a mix of eicosapentaenoic acid, docosahexaenoic acid, and γ-linolenic acid as an ADHD-specific intervention. Controlled studies support the elimination of artificial food dyes to reduce ADHD symptoms, but this treatment may be more applicable to the general pediatric population than to children with diagnosed ADHD. Mineral supplementation is indicated for those with documented deficiencies but is not supported for others with ADHD. Carnitine may have a role for inattention, but the evidence is limited. Dimethylaminoethanol probably has a small effect. Herbs, although “natural,” are actually crude drugs, which along with homeopathic treatments have little evidence of efficacy. Consequences of delayed proven treatments need consideration in the risk–benefit assessment of dietary/nutritional treatments.
Literatur
1.
Zurück zum Zitat American Psychiatric Association. Diagnostic and statistical manual of mental disorders (revised 4th ed.). Washington: American Psychiatric Association; 2000. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (revised 4th ed.). Washington: American Psychiatric Association; 2000.
2.
Zurück zum Zitat Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004;14:11–28.PubMedCrossRef Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behavior disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004;14:11–28.PubMedCrossRef
3.
Zurück zum Zitat Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40:168–79.PubMedCrossRef Swanson JM, Kraemer HC, Hinshaw SP, et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry. 2001;40:168–79.PubMedCrossRef
5.
Zurück zum Zitat Kemper KJ, O’Connor KG. Pediatricians’ recommendations for complementary and alternative medical (CAM) therapies. Ambul Pediatr. 2004;4:482–7.PubMedCrossRef Kemper KJ, O’Connor KG. Pediatricians’ recommendations for complementary and alternative medical (CAM) therapies. Ambul Pediatr. 2004;4:482–7.PubMedCrossRef
6.
Zurück zum Zitat •• Arnold LE, Hurt EA, Mayes T, Lofthouse N. Ingestible alternative and complementary treatments for attention-deficit/hyperactivity disorder. In: Hoza B, Evans, SW, editors. Treating attention-deficit disorder. Kingston: Civic Research Institute; 2011. This chapter provides an evaluation of the current research support for ingestible CAM treatments of pediatric ADHD. •• Arnold LE, Hurt EA, Mayes T, Lofthouse N. Ingestible alternative and complementary treatments for attention-deficit/hyperactivity disorder. In: Hoza B, Evans, SW, editors. Treating attention-deficit disorder. Kingston: Civic Research Institute; 2011. This chapter provides an evaluation of the current research support for ingestible CAM treatments of pediatric ADHD.
7.
Zurück zum Zitat Chan E, Rappaport LA, Kemper KJ. Complementary and alternative therapies in childhood attention and hyperactivity problems. J Dev Behav Pediatr. 2003;24:4–8.PubMedCrossRef Chan E, Rappaport LA, Kemper KJ. Complementary and alternative therapies in childhood attention and hyperactivity problems. J Dev Behav Pediatr. 2003;24:4–8.PubMedCrossRef
8.
Zurück zum Zitat Benton D, Roberts G. Effect of vitamin and mineral supplementation on intelligence of a sample of schoolchildren. Lancet. 1988;331:140–3.CrossRef Benton D, Roberts G. Effect of vitamin and mineral supplementation on intelligence of a sample of schoolchildren. Lancet. 1988;331:140–3.CrossRef
9.
Zurück zum Zitat Benton D, Cook R. Vitamin and mineral supplements improve the intelligence scores and concentration of six-year-old children. Personal Individ Differ. 1991;12:1151–8.CrossRef Benton D, Cook R. Vitamin and mineral supplements improve the intelligence scores and concentration of six-year-old children. Personal Individ Differ. 1991;12:1151–8.CrossRef
10.
Zurück zum Zitat Crombie IK, Flory C, Todman J, et al. Effect of vitamin and mineral supplementation on verbal and nonverbal reasoning of schoolchildren. Lancet. 1990;335:744–7.PubMedCrossRef Crombie IK, Flory C, Todman J, et al. Effect of vitamin and mineral supplementation on verbal and nonverbal reasoning of schoolchildren. Lancet. 1990;335:744–7.PubMedCrossRef
11.
Zurück zum Zitat Benton D, Buts JP. Vitamin/mineral supplementation and intelligence. Lancet. 1990;335:1158–60.PubMedCrossRef Benton D, Buts JP. Vitamin/mineral supplementation and intelligence. Lancet. 1990;335:1158–60.PubMedCrossRef
12.
Zurück zum Zitat McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:1560–7.PubMedCrossRef McCann D, Barrett A, Cooper A, et al. Food additives and hyperactive behaviour in 3-year-old and 8/9-year-old children in the community: a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:1560–7.PubMedCrossRef
13.
Zurück zum Zitat Stevens LJ, Zentall SS, Deck JL, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr. 1995;62:761–8.PubMed Stevens LJ, Zentall SS, Deck JL, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. Am J Clin Nutr. 1995;62:761–8.PubMed
14.
Zurück zum Zitat Spahis S, Vanasse M, Belanger SA, et al. Lipid profile, fatty acid composition and pro- and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids. 2008;79:47–53.PubMedCrossRef Spahis S, Vanasse M, Belanger SA, et al. Lipid profile, fatty acid composition and pro- and anti-oxidant status in pediatric patients with attention-deficit/hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids. 2008;79:47–53.PubMedCrossRef
15.
Zurück zum Zitat Brookes KJ, Chen W, Xu X, et al. Association of fatty acid desaturase genes with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;60:1053–61.PubMedCrossRef Brookes KJ, Chen W, Xu X, et al. Association of fatty acid desaturase genes with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;60:1053–61.PubMedCrossRef
16.
Zurück zum Zitat Belanger SA, Vanasse M, Spahis S, et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatr Child Health. 2009;14:89–98.PubMed Belanger SA, Vanasse M, Spahis S, et al. Omega-3 fatty acid treatment of children with attention-deficit hyperactivity disorder: a randomized, double-blind, placebo-controlled study. Paediatr Child Health. 2009;14:89–98.PubMed
17.
Zurück zum Zitat Gustafsson PA, Birberg-Thornberg U, Duchen K, et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr. 2010;99:1540–9.PubMedCrossRef Gustafsson PA, Birberg-Thornberg U, Duchen K, et al. EPA supplementation improves teacher-rated behaviour and oppositional symptoms in children with ADHD. Acta Paediatr. 2010;99:1540–9.PubMedCrossRef
18.
Zurück zum Zitat Arnold LE, Kleykamp D, Votolato NA, et al. Gamma-linolenic acid for attention-deficit/hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biol Psychiatry. 1989;25:222–8.PubMedCrossRef Arnold LE, Kleykamp D, Votolato NA, et al. Gamma-linolenic acid for attention-deficit/hyperactivity disorder: placebo-controlled comparison to D-amphetamine. Biol Psychiatry. 1989;25:222–8.PubMedCrossRef
19.
Zurück zum Zitat Calarge C, Farmer C, DiSilvestro R, Arnold LE. Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2010;20:495–502.PubMedCrossRef Calarge C, Farmer C, DiSilvestro R, Arnold LE. Serum ferritin and amphetamine response in youth with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2010;20:495–502.PubMedCrossRef
20.
Zurück zum Zitat Oner P, Oner O. Relationship of ferritin to symptom ratings children with attention deficit hyperactivity disorder: effect of comorbidity. Child Psychiatry Hum Dev. 2008;39:323–30.PubMedCrossRef Oner P, Oner O. Relationship of ferritin to symptom ratings children with attention deficit hyperactivity disorder: effect of comorbidity. Child Psychiatry Hum Dev. 2008;39:323–30.PubMedCrossRef
21.
Zurück zum Zitat Sever Y, Ashkenazi A, Tyano S, Weizman A. Iron treatment in children with attention-deficit/hyperactivity disorder: a preliminary report. Neuropsychobiology. 1997;35:178–80.PubMedCrossRef Sever Y, Ashkenazi A, Tyano S, Weizman A. Iron treatment in children with attention-deficit/hyperactivity disorder: a preliminary report. Neuropsychobiology. 1997;35:178–80.PubMedCrossRef
22.
Zurück zum Zitat Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol. 2008;38:20–6.PubMedCrossRef Konofal E, Lecendreux M, Deron J, et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol. 2008;38:20–6.PubMedCrossRef
23.
Zurück zum Zitat Conners CK. Food additives and hyperactive children. London: Plenum; 1980. Conners CK. Food additives and hyperactive children. London: Plenum; 1980.
24.
Zurück zum Zitat National Institutes of Health. NIH consensus development conference: defined diets and childhood hyperactivity. Clin Pediatr. 1982;21:627–30.CrossRef National Institutes of Health. NIH consensus development conference: defined diets and childhood hyperactivity. Clin Pediatr. 1982;21:627–30.CrossRef
26.
Zurück zum Zitat Pelsser LM, Frankena K, Toorman J, et al. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet. 2011;377:494–503.PubMedCrossRef Pelsser LM, Frankena K, Toorman J, et al. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet. 2011;377:494–503.PubMedCrossRef
27.
Zurück zum Zitat Bateman B, Warner JO, Hutchinson E, et al. The effects of a double blind, placebo controlled artificial food colourings and benzoate preservative challenge on hyperactivity in a general population sample of preschool children. Arch Dis Child. 2004;89:506–11.PubMedCrossRef Bateman B, Warner JO, Hutchinson E, et al. The effects of a double blind, placebo controlled artificial food colourings and benzoate preservative challenge on hyperactivity in a general population sample of preschool children. Arch Dis Child. 2004;89:506–11.PubMedCrossRef
28.
Zurück zum Zitat Van Oudheusden LJ, Scholte HR. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids. 2002;67:33–8.PubMedCrossRef Van Oudheusden LJ, Scholte HR. Efficacy of carnitine in the treatment of children with attention-deficit hyperactivity disorder. Prostaglandins Leukot Essent Fatty Acids. 2002;67:33–8.PubMedCrossRef
29.
Zurück zum Zitat Arnold LE, Amato A, Bozzolo H, et al. Acetyl-L-Carnitine in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 2007;17:791–801.PubMedCrossRef Arnold LE, Amato A, Bozzolo H, et al. Acetyl-L-Carnitine in attention-deficit/hyperactivity disorder: a multi-site, placebo-controlled pilot trial. J Child Adolesc Psychopharmacol. 2007;17:791–801.PubMedCrossRef
30.
Zurück zum Zitat Abbasi SH, Heidari S, Mohammadi MR, et al. Acetyl-l-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial. Child Psychiatry Hum Dev 2011, published online ahead of print. Abbasi SH, Heidari S, Mohammadi MR, et al. Acetyl-l-carnitine as an adjunctive therapy in the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a placebo-controlled trial. Child Psychiatry Hum Dev 2011, published online ahead of print.
31.
Zurück zum Zitat Ferrari R, Merli E, Ciccitelli G, et al. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci. 2004;1033:79–91.PubMedCrossRef Ferrari R, Merli E, Ciccitelli G, et al. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci. 2004;1033:79–91.PubMedCrossRef
32.
Zurück zum Zitat Re O. 2- Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action. Curr Therap Res Clin Exp. 1974;16:1238–42. Re O. 2- Dimethylaminoethanol (deanol): a brief review of its clinical efficacy and postulated mechanism of action. Curr Therap Res Clin Exp. 1974;16:1238–42.
33.
Zurück zum Zitat Lewis JA, Young R. Deanol and methylphenidate in minimal brain dysfunction. Int J Clin Pharmacol Ther. 1975;17:534–40. Lewis JA, Young R. Deanol and methylphenidate in minimal brain dysfunction. Int J Clin Pharmacol Ther. 1975;17:534–40.
34.
Zurück zum Zitat Arnold LE, Votolato NA, Kleykamp D, et al. Does hair zinc predict amphetamine improvement of ADHD/hyperactivity? Int J Neurosci. 1990;50:103–7.PubMedCrossRef Arnold LE, Votolato NA, Kleykamp D, et al. Does hair zinc predict amphetamine improvement of ADHD/hyperactivity? Int J Neurosci. 1990;50:103–7.PubMedCrossRef
35.
Zurück zum Zitat Bilici M, Yildirim F, Kandil S, et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:181–90.PubMedCrossRef Bilici M, Yildirim F, Kandil S, et al. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:181–90.PubMedCrossRef
36.
Zurück zum Zitat Uckardes Y, Ozmert EN, Unal F, Yurdakok K. Effects of zinc supplementation on parent and teacher behavior rating scores in low socioeconomic level Turkish primary school children. Acta Paediatri. 2009;98:731–6.CrossRef Uckardes Y, Ozmert EN, Unal F, Yurdakok K. Effects of zinc supplementation on parent and teacher behavior rating scores in low socioeconomic level Turkish primary school children. Acta Paediatri. 2009;98:731–6.CrossRef
37.
Zurück zum Zitat Akhondzadeh S, Mohammadi M, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. BMC Psychiatry. 2004;4. Akhondzadeh S, Mohammadi M, Khademi M. Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. BMC Psychiatry. 2004;4.
38.
Zurück zum Zitat • Arnold LE, DiSilvestro RA, Bozzolo D, et al. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. J Child Adolesc Psychopharmacol 2011;21:1–19. This article is one of the few studies to evaluate CAM treatments as complementary treatments to standard stimulant medication. PubMedCrossRef • Arnold LE, DiSilvestro RA, Bozzolo D, et al. Zinc for attention-deficit/hyperactivity disorder: placebo-controlled double-blind pilot trial alone and combined with amphetamine. J Child Adolesc Psychopharmacol 2011;21:1–19. This article is one of the few studies to evaluate CAM treatments as complementary treatments to standard stimulant medication. PubMedCrossRef
39.
Zurück zum Zitat Kozielec T, Starobrat-Hermelin B, Kotkowiak L. Deficiency of certain trace elements in children with hyperactivity. Psychiatria Polska. 1994;28:345–53.PubMed Kozielec T, Starobrat-Hermelin B, Kotkowiak L. Deficiency of certain trace elements in children with hyperactivity. Psychiatria Polska. 1994;28:345–53.PubMed
40.
Zurück zum Zitat Mousain-Bosc M, Roche M, Poige A, et al. Improvements of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. Magnes Res. 2006;19:46–52.PubMed Mousain-Bosc M, Roche M, Poige A, et al. Improvements of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. Magnes Res. 2006;19:46–52.PubMed
41.
Zurück zum Zitat Mousain-Bosc M, Roche M, Rapin J, Bali JP. Magnesium VitB6 intake reduces central nervous system hyperexcitability in children. J Am Coll Nutr. 2004;23:545S–8S.PubMed Mousain-Bosc M, Roche M, Rapin J, Bali JP. Magnesium VitB6 intake reduces central nervous system hyperexcitability in children. J Am Coll Nutr. 2004;23:545S–8S.PubMed
42.
Zurück zum Zitat Nogovitsina OR, Levitina EV. Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Biol Psychiatry. 2007;37:199–202. Nogovitsina OR, Levitina EV. Neurological aspects of the clinical features, pathophysiology, and corrections of impairments in attention deficit hyperactivity disorder. Neurosci Biol Psychiatry. 2007;37:199–202.
43.
Zurück zum Zitat Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention-deficit/hyperactivity disorder (ADHD): positive response to magnesium oral loading test. Magnes Res. 1997;10:149–56.PubMed Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention-deficit/hyperactivity disorder (ADHD): positive response to magnesium oral loading test. Magnes Res. 1997;10:149–56.PubMed
44.
Zurück zum Zitat Izenwasser SE, Garcia-Valdez K, Kantak KM. Stimulant-like effects of magnesium on aggression in mice. Pharmacol Biochem Behav. 1986;25:1195–9.PubMedCrossRef Izenwasser SE, Garcia-Valdez K, Kantak KM. Stimulant-like effects of magnesium on aggression in mice. Pharmacol Biochem Behav. 1986;25:1195–9.PubMedCrossRef
45.
Zurück zum Zitat Durlach J, Durlach V, Bac P, et al. Magnesium and therapeutics. Magnes Res. 1994;7:313–28.PubMed Durlach J, Durlach V, Bac P, et al. Magnesium and therapeutics. Magnes Res. 1994;7:313–28.PubMed
46.
Zurück zum Zitat Dykman KD, Dykman RA. Effect of nutritional supplements on attentional-deficit hyperactivity disorder. Integr Physiol Behav Sci. 1998;33:49–60.PubMedCrossRef Dykman KD, Dykman RA. Effect of nutritional supplements on attentional-deficit hyperactivity disorder. Integr Physiol Behav Sci. 1998;33:49–60.PubMedCrossRef
47.
Zurück zum Zitat Dykman KD, McKinley R. Effect of Glyconutritionals on the severity of ADHD. Proc Fish Inst Med Res. 1997;1:24–5. Dykman KD, McKinley R. Effect of Glyconutritionals on the severity of ADHD. Proc Fish Inst Med Res. 1997;1:24–5.
48.
Zurück zum Zitat Kaplan BJ, Fisher JE, Crawford SG, et al. Improved mood and behavior during treatment with a mineral-vitamin supplement: an open-label case series of children. J Child Adolesc Psychopharmacol. 2004;14:115–22.PubMedCrossRef Kaplan BJ, Fisher JE, Crawford SG, et al. Improved mood and behavior during treatment with a mineral-vitamin supplement: an open-label case series of children. J Child Adolesc Psychopharmacol. 2004;14:115–22.PubMedCrossRef
49.
Zurück zum Zitat • Rucklidge J, Taylor M, Whitehead K. Effect of micronutrients on behavior and mood in adults with ADHD: evidence from an 8-week open label trial with natural extension. J Attent Disord 2011;15:79–91. This article is one of the few studies to evaluate CAM treatments for adults with ADHD. PubMedCrossRef • Rucklidge J, Taylor M, Whitehead K. Effect of micronutrients on behavior and mood in adults with ADHD: evidence from an 8-week open label trial with natural extension. J Attent Disord 2011;15:79–91. This article is one of the few studies to evaluate CAM treatments for adults with ADHD. PubMedCrossRef
50.
Zurück zum Zitat Harding KL, Judah RD, Gant CE. Outcome-based comparison of Ritalin versus food-supplement treated children with ADHD. Altern Med Rev. 2003;8:319–30.PubMed Harding KL, Judah RD, Gant CE. Outcome-based comparison of Ritalin versus food-supplement treated children with ADHD. Altern Med Rev. 2003;8:319–30.PubMed
51.
Zurück zum Zitat Krummel DA, Seligson FH, Guthrie HA. Hyperactivity: is candy causal? Crit Rev Food Sci Nutr. 1996;36:31–47.PubMedCrossRef Krummel DA, Seligson FH, Guthrie HA. Hyperactivity: is candy causal? Crit Rev Food Sci Nutr. 1996;36:31–47.PubMedCrossRef
52.
Zurück zum Zitat Wolraich ML, Lindgren SD, Stumbo PJ, et al. Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. N Engl J Med. 1994;330:301–7.PubMedCrossRef Wolraich ML, Lindgren SD, Stumbo PJ, et al. Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. N Engl J Med. 1994;330:301–7.PubMedCrossRef
53.
Zurück zum Zitat Wesnes KA, Pincock C, Richardson D, et al. Breakfast reduces declines in attention and memory over the morning in schoolchildren. Appetite. 2003;41:329–31.PubMedCrossRef Wesnes KA, Pincock C, Richardson D, et al. Breakfast reduces declines in attention and memory over the morning in schoolchildren. Appetite. 2003;41:329–31.PubMedCrossRef
54.
Zurück zum Zitat Bornstein RA, Baker GB, Carroll A, et al. Plasma amino acids in attention deficit disorder. Psychiatry Res. 1990;33:301–6.PubMedCrossRef Bornstein RA, Baker GB, Carroll A, et al. Plasma amino acids in attention deficit disorder. Psychiatry Res. 1990;33:301–6.PubMedCrossRef
55.
Zurück zum Zitat Stein TP, Sammaritano AM. Nitrogen metabolism in normal and hyperkinetic boys. Am J Clin Nutr. 1984;39:520–4.PubMed Stein TP, Sammaritano AM. Nitrogen metabolism in normal and hyperkinetic boys. Am J Clin Nutr. 1984;39:520–4.PubMed
56.
Zurück zum Zitat Nemzer E, Arnold LE, Votolato NA, McConnell H. Amino Acid supplementation as therapy for attention deficit disorder (ADD). J Am Acad Child Adolesc Psychiatry. 1986;25:509–13.CrossRef Nemzer E, Arnold LE, Votolato NA, McConnell H. Amino Acid supplementation as therapy for attention deficit disorder (ADD). J Am Acad Child Adolesc Psychiatry. 1986;25:509–13.CrossRef
57.
Zurück zum Zitat Zametkin AJ, Karoum F, Rapoport J. Treatment of hyperactive children with d-phenylalanine. Am J Psychiatry. 1987;144:792–4.PubMed Zametkin AJ, Karoum F, Rapoport J. Treatment of hyperactive children with d-phenylalanine. Am J Psychiatry. 1987;144:792–4.PubMed
58.
Zurück zum Zitat Arnold LE, Christopher J, Huestis RD, Smeltzer DJ. Megavitamins for minimal brain dysfunction: a placebo-controlled study. JAMA. 1978;240:2642–3.PubMedCrossRef Arnold LE, Christopher J, Huestis RD, Smeltzer DJ. Megavitamins for minimal brain dysfunction: a placebo-controlled study. JAMA. 1978;240:2642–3.PubMedCrossRef
59.
Zurück zum Zitat Brenner A. The effects of megadoses of selected B complex vitamins on children with hyperkinesis; controlled studies with long-term follow-up. J Learn Disabil. 1982;15:258–64.PubMedCrossRef Brenner A. The effects of megadoses of selected B complex vitamins on children with hyperkinesis; controlled studies with long-term follow-up. J Learn Disabil. 1982;15:258–64.PubMedCrossRef
60.
Zurück zum Zitat Canadian Paediatric Society. Megavitamin and megamineral therapy in childhood. Can Med Assoc J. 1990;143:1009–113. Canadian Paediatric Society. Megavitamin and megamineral therapy in childhood. Can Med Assoc J. 1990;143:1009–113.
61.
Zurück zum Zitat McGuire JK, Kulkarni MS, Baden HP. Fatal hypermagnesemia in a child treated with megavitamin/megamineral therapy. Pediatrics. 2000;105:E18.PubMedCrossRef McGuire JK, Kulkarni MS, Baden HP. Fatal hypermagnesemia in a child treated with megavitamin/megamineral therapy. Pediatrics. 2000;105:E18.PubMedCrossRef
62.
Zurück zum Zitat Trebaticka J, Kopasova S, Hradecna Z, et al. Treatment of ADHD with French maritime pine bark extract, Pycnogenol. Eur Child Adolesc Psychiatry. 2006;15:329–35.PubMedCrossRef Trebaticka J, Kopasova S, Hradecna Z, et al. Treatment of ADHD with French maritime pine bark extract, Pycnogenol. Eur Child Adolesc Psychiatry. 2006;15:329–35.PubMedCrossRef
63.
Zurück zum Zitat Tenenbaum S, Paull JC, Sparrow EP, et al. An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). J Atten Disord. 2002;6:49–60.PubMedCrossRef Tenenbaum S, Paull JC, Sparrow EP, et al. An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD). J Atten Disord. 2002;6:49–60.PubMedCrossRef
64.
Zurück zum Zitat Weber W, Stoep AV, McCarty RL, et al. Hypericum perforatum (St John’s Wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. JAMA. 2008;299:2633–41.PubMedCrossRef Weber W, Stoep AV, McCarty RL, et al. Hypericum perforatum (St John’s Wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. JAMA. 2008;299:2633–41.PubMedCrossRef
65.
Zurück zum Zitat Salehi B, Imani R, Mohammadi MR, et al. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:76–80.PubMedCrossRef Salehi B, Imani R, Mohammadi MR, et al. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:76–80.PubMedCrossRef
66.
Zurück zum Zitat Lyon MR, Cline JC, De Zepetnek JT, et al. Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot study. J Psychiatry Neurosci. 2001;26:221–8.PubMed Lyon MR, Cline JC, De Zepetnek JT, et al. Effect of the herbal extract combination Panax quinquefolium and Ginkgo biloba on attention-deficit hyperactivity disorder: a pilot study. J Psychiatry Neurosci. 2001;26:221–8.PubMed
67.
Zurück zum Zitat Katz M, Levine AA, Kol-Degani H, Kav-Venaki L. A compound herbal preparation (CHP) in the treatment of children with ADHD: a randomized controlled trial. J Atten Disord. 2010;14:281–91.PubMedCrossRef Katz M, Levine AA, Kol-Degani H, Kav-Venaki L. A compound herbal preparation (CHP) in the treatment of children with ADHD: a randomized controlled trial. J Atten Disord. 2010;14:281–91.PubMedCrossRef
68.
Zurück zum Zitat Lamont J. Homeopathic treatment of attention deficit hyperactivity disorder. Br Homeopath J. 1997;86:196–200.CrossRef Lamont J. Homeopathic treatment of attention deficit hyperactivity disorder. Br Homeopath J. 1997;86:196–200.CrossRef
69.
Zurück zum Zitat Frei H, Everts R, von Ammon K, et al. Homeopathic treatment of children with attention deficit hyperactivity disorder: a randomised, double blind, placebo controlled crossover trial. Eur J Pediatr. 2005;164:758–67.PubMedCrossRef Frei H, Everts R, von Ammon K, et al. Homeopathic treatment of children with attention deficit hyperactivity disorder: a randomised, double blind, placebo controlled crossover trial. Eur J Pediatr. 2005;164:758–67.PubMedCrossRef
70.
Zurück zum Zitat Strauss LC. The efficacy of a homeopathic preparation in the management of attention deficit hyperactivity disorder. J Biomed Ther. 2000;18:197–201. Strauss LC. The efficacy of a homeopathic preparation in the management of attention deficit hyperactivity disorder. J Biomed Ther. 2000;18:197–201.
71.
Zurück zum Zitat Jacobs J, Williams AL, Girard C, et al. Homeopathy for attention-deficit/hyperactivity disorder: a pilot randomized-controlled trial. J Altern Complement Med. 2005;11:799–806.PubMedCrossRef Jacobs J, Williams AL, Girard C, et al. Homeopathy for attention-deficit/hyperactivity disorder: a pilot randomized-controlled trial. J Altern Complement Med. 2005;11:799–806.PubMedCrossRef
Metadaten
Titel
Dietary and Nutritional Treatments for Attention-Deficit/Hyperactivity Disorder: Current Research Support and Recommendations for Practitioners
verfasst von
Elizabeth A. Hurt
L. Eugene Arnold
Nicholas Lofthouse
Publikationsdatum
01.10.2011
Verlag
Current Science Inc.
Erschienen in
Current Psychiatry Reports / Ausgabe 5/2011
Print ISSN: 1523-3812
Elektronische ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-011-0217-z

Weitere Artikel der Ausgabe 5/2011

Current Psychiatry Reports 5/2011 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Typ-2-Diabetes und Depression folgen oft aufeinander

14.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes sind überdurchschnittlich gefährdet, in den nächsten Jahren auch noch eine Depression zu entwickeln – und umgekehrt. Besonders ausgeprägt ist die Wechselbeziehung laut GKV-Daten bei jüngeren Erwachsenen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Spezielles Sportprogramm bei einer Reihe von psychischen Erkrankungen effektiv

08.05.2024 Psychotherapie Nachrichten

Sportliche Betätigung hilft nicht nur bei Depression, sondern auch in Gruppen von Patientinnen und Patienten mit unterschiedlichen psychischen Erkrankungen, wie Insomnie, Panikattacken, Agoraphobie und posttraumatischem Belastungssyndrom. Sie alle profitieren längerfristig.

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.